RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.

NCT02176122 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

391

Enrollment

OTHER

Sponsor class

Stopped Secondary to third interim analysis by the study DSMB.

Conditions

Bloodstream Infections

Interventions

DRUG: Meropenem
DRUG: Piperacillin-tazobactam combination product

Sponsor

The University of Queensland

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]